GlobeNewswire by notified

NOTICE TO TRAINERS’ HOUSE PLC’S ANNUAL GENERAL MEETING

Share

TRAINERS’ HOUSE PLC STOCK EXCHANGE RELEASE 7 MARCH 2023 AT 15:15

The shareholders of Trainers' House Plc are invited to the annual general meeting, which will be held on 29 March 2023 at 13:30 at the company's office at Tammasaarenlaituri 3, 00180 Helsinki. Reception of those registered for the meeting at the meeting place starts at 13:15.

A. Agenda of the general meeting

At the annual general meeting, the following matters will be considered:

1. Opening of the meeting

2. Calling the meeting to order

3. Election of persons to scrutinize the minutes and to supervise the counting of votes

4. Recording the legality of the meeting

5. Recording the attendance at the meeting and adoption of the list of votes

6. Presentation of the financial statements, the report of the Board of Directors and the auditor’s report for the financial year 2022

- Presentation of the CEO’s review.

The financial statements, report of the Board of Directors and auditor's report are available on the company's website www.trainershouse.fi.

7. Adoption of the financial statements

8. Resolution on the use of the profit shown on the balance sheet and the distribution of dividend

The Board of Directors proposes to the annual general meeting on 29 March 2023 that from the retained earnings a dividend of EUR 0.47 per share be paid out on the shares of the Company.

The dividend will be paid in two instalments:

-     EUR 0.26 on 26 April 2023 (record date 19 April 2023)

-     EUR 0.21 on 21 December 2023 (record date 14 December 2023)

The dividend will be paid to shareholders registered in the register of shareholders of the company on the record date of the dividend payment.

9. Resolution on the discharge of the members of the Board of Directors and the managing director from liability

10. Consideration of the remuneration report of the governing bodies

The remuneration report is available on the company's website www.trainershouse.fi.

11. Resolution on the remuneration of the members of the Board of Directors

The shareholders of Trainers’ House Plc representing a total of approximately 47.7% of the company's shares and votes, have informed the company that they will propose at the annual general meeting that the chairperson of the board will be paid 4,500 euros per month and the member 2,500 euros per month.

12. Resolution on the number of members of the Board of Directors

The shareholders of Trainers’ House Plc representing a total of approximately 47.7% of the company's shares and votes, have informed the company that they will propose at the annual general meeting that the number of board members will be confirmed at five (5).

13. Election of members of the Board of Directors

The shareholders of Trainers’ House Plc representing a total of approximately 47.7% of the company's shares and votes, have informed the company that they will propose at the annual general meeting that Aarne Aktan, Jari Sarasvuo, Jarmo Hyökyvaara and Elma Palsila will be re-elected as board members and Emilia Tauriainen elected as a new member.

14. Resolution on the remuneration of the auditor

The board proposes that the auditor be remunerated fee according to the auditor's reasonable invoice.

15. Election of auditor

The board proposes that Ernst & Young Oy will be chosen to continue as the company's auditor.

16. The board's proposal to change the Articles of Association

The Board of Directors proposes to the annual general meeting that the annual general meeting should decide on amending Article 12 of the Articles of Association so that the general meeting could be held without a physical meeting place as a remote meeting. According to the proposal, a new paragraph would be added to Article 12 of the Articles of Association, which would read in its entirety as follows:

"The board can decide that the general meeting is held without a meeting place whereby the shareholders shall exercise their power of decision in full in real-time during the meeting using telecommunication connection and technical means (remote meeting).”

17. Closing of the meeting

B. Documents of the general meeting

The above-mentioned proposals for resolutions on the agenda of the annual general meeting and this notice are available on Trainers’ House Plc's website at www.trainershouse.fi. Trainers’ House Plc's financial atatements, annual report, auditor's report, and remuneration report are available on the aforementioned website. Copies of the proposals and other documents are also available at the meeting.

The minutes of the annual general meeting will be available on the aforementioned website no later than two weeks from the date of the annual general meeting.

C. Instructions for meeting participants

1. Shareholder registered in the shareholders' register

Shareholders who are registered in the shareholders' register held by Euroclear Finland Oy on the record date of 17 March 2023, are entitled to participate in annual general meeting. A shareholder whose shares in the company are registered in his/her personal Finnish book-entry account is registered in the company's shareholders' register.

Registration for the annual general meeting starts on 7 March 2023. A shareholder entered in the company's shareholders' register who wishes to attend the annual general meeting must register no later than 23 March 2023 at 16:00 (EET), by which time the registration must be received.

Registration for the annual general meeting can be done by mail to Trainers' House Plc, Tammasaarenlaituri 3, 00180 Helsinki, Finland or by telephone to number +358 50 430 7039 or by e-mail to iiris.nummila@trainershouse.fi.

When registering, the shareholder must provide the shareholder's name, identification number, address, telephone number and the name and identification number of any assistant or proxy. The personal data provided by shareholders to the Company will only be used in connection with the annual general meeting and the processing of the related necessary registrations.

2. Holder of nominee-registered shares

A holder of nominee-registered shares is entitled to participate in the annual general meeting based on the shares which would entitle him/her to be entered in the shareholders' register kept by Euroclear Finland Oy on the record date for the general meeting 17 March 2023. Participation also requires that the shareholder is temporarily registered in the shareholders' register held by Euroclear Finland Oy by 24 March 2023 by 10:00 (EET) at the latest. In the case of nominee-registered shares, this is considered as registration for the annual general meeting. Changes in the shareholding after the record date of the General Meeting do not affect the right to participate in the annual general meeting or the shareholder's voting rights.

The holder of nominee-registered shares is advised to request well in advance the necessary instructions from his/her custodian bank regarding the temporary registration in the register of shareholders, the issuing of proxies and voting instructions and registration to the meeting. The account manager of the custodian bank shall register the holder of nominee-registered shares who wish to attend the general meeting temporarily in the register of shareholders of the company by the aforementioned date and time at the latest.

3. Proxy representatives and powers of attorney

A shareholder may attend the annual general meeting and exercise his/her rights there through a proxy representative.

The shareholder's proxy must present dated proxy documents, or otherwise in a reliable manner prove that he/she is entitled to represent the shareholder at the annual general meeting. If a shareholder participates in the annual general meeting by means of several proxy representatives, who represent the shareholder with shares on different securities accounts, the shares by which each proxy representative represents the shareholder shall be identified in connection with the registration to the meeting.

Possible proxy documents are requested to be delivered to the address mentioned above for registrations before the period for giving a notice to attend the meeting terminates by e-mail or mail. In addition to delivering the proxy documents, the shareholder or the proxy representative must take care of registration to the meeting as described previously in this notice.

4. Other information

The language of the meeting is Finnish.

Shareholders present at the annual general meeting have the right to ask questions about the matters discussed at the meeting in accordance with Chapter 5, Section 25 of the Finnish Limited Liability Companies Act.

Changes in the shareholding after the record date of the annual general meeting do not affect the right to participate in the annual general meeting or the shareholder's voting rights.

On the date of the notice of annual general meeting, Trainers’ House Plc has a total of 2.147.826  shares representing the same number of votes. 

In Helsinki 7 March 2023

TRAINERS’ HOUSE PLC

Board of Directors

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)16.4.2024 23:30:00 CEST | Press release

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of StelaraSELARSDI was developed and is manufactured by Alvotech using murine cell (Sp2/0) and a continuous perfusion process, which are the same type of cells and process used for the production of Stelara REYKJAVIK, ICELAND & PARSIPPANY, NJ — Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Unde

Atico Reports Consolidated Financial Results for 202316.4.2024 22:30:29 CEST | Press release

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) today announced its financial results for the year ended December 31, 2023, posting income from mining operations of $7.4 million and a net loss of $5.8 million. Production for the year at Atico’s El Roble mine totaled 13.2 million pounds (“lbs”) of copper and 10,149 ounces (“oz”) of gold in concentrate at a cash cost(1) of $2.04 per payable pound of copper(2). Fernando E. Ganoza, CEO and Director, commented, "we had a challenging year overall, with the first half of the year facing lower than expected head grades and lower throughput due to mechanical and operational issues, coupled with a significant appreciation in the Colombian Peso throughout the year which materially increased our costs. Despite these challenges the team did a great job getting El Roble mine back on track in the

Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program16.4.2024 22:10:00 CEST | Press release

Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% The operational adjustment plan extends the anticipated cash runway to the fourth quarter of 2025, through the readout from the Phase II DOVACC trial Oslo, April 16, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces a plan to optimize its business operations to support the continuous advancement of UV1 and long-term business growth. “We remain dedicated to our investigation of the potential impact of UV1 vaccine across several c

ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations16.4.2024 22:05:00 CEST | Press release

ASPIRE-FTD Sites in the EU and U.S. to Use ClearPoint® Navigation Together With SmartFlow® Cannula for Intrathalamic Gene Therapy Administration SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patient in the ASPIRE-FTD Phase 1/2 clinical trial evaluating its investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) mutations. “FTD is an important cause of dementia in people under 65 and has a devastating impact on patients and families. The importance of accurately delivering this one-time gene therapy to the thalamus, while minimizing systemic exposure, is the precise use case of ClearPoint’s minimally invasive platform for gene and cell delivery,” stated Jeremy Stigall, Chief Business Officer at ClearPoin

Nokia Corporation: Repurchase of own shares on 16.04.202416.4.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 16 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 16.04.2024 Espoo, Finland – On 16 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL557,6403.17CEUX--BATE--AQEU--TQEX--Total557,6403.17 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

HiddenA line styled icon from Orion Icon Library.Eye